Philadelphia, PA, May 16, 2013 – The relationship between the heritable risk for schizophrenia and low intelligence (IQ) has not been clear. Schizophrenia is commonly associated with cognitive impairments that may cause functional disability. There are clues that reduced IQ may be linked to the risk for developing schizophrenia. For example, reduced cognitive ability may precede the onset of schizophrenia symptoms. Also, these deficits may be present in healthy relatives of people diagnosed with schizophrenia.
In a remarkable new study published in Biological Psychiatry, Dr. Andrew McIntosh and his colleagues at the University of Edinburgh provide new evidence that the genetic risk for schizophrenia is associated with lower IQ among people who do not develop this disorder.
The authors analyzed data from 937 individuals in Scotland who first completed IQ testing in 1947, at age 11. Around age 70, they were retested and their DNA was analyzed to estimate their genetic risk for schizophrenia.
The researchers found that individuals with a higher genetic risk for schizophrenia had a lower IQ at age 70 but not at age 11. Having more schizophrenia risk-related gene variants was also associated with a greater decline in lifelong cognitive ability.
"If nature has loaded a person's genes towards schizophrenia, then there is a slight but detectable worsening in cognitive function between childhood and old age. With further research into how these genes affect the brain, it could become possible to understand how genes linked to schizophrenia affect people's cognitive function," said McIntosh.
These findings suggest that common genetic variants may underlie both cognitive aging and risk of schizophrenia.
"While this study does not show that these common gene variants produce schizophrenia per se, it elegantly suggests that these variants may contribute to declines in intelligence, a clinical feature associated with schizophrenia," commented Dr. John Krystal, Editor of Biological Psychiatry. "However, we have yet to understand the development of cognitive impairments that produce disability in young adulthood, the period when schizophrenia develops for many affected people."
Clearly, more research is necessary, but this new study adds to the growing and substantial effort to understand how the gene variants that contribute to the development of schizophrenia give rise to the cognitive disability commonly associated with it.
The article is "Polygenic Risk for Schizophrenia Is Associated with Cognitive Change Between Childhood and Old Age" by Andrew M. McIntosh, Alan Gow, Michelle Luciano, Gail Davies, David C. Liewald, Sarah E. Harris, Janie Corley, Jeremy Hall, John M. Starr, David J. Porteous, Albert Tenesa, Peter M. Visscher, and Ian J. Deary (doi: 10.1016/j.biopsych.2013.01.011). The article appears in Biological Psychiatry, Volume 73, Issue 10 (May 15, 2013), published by Elsevier.
Notes for Editors
Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or Biol.Psych@utsouthwestern.edu. Journalists wishing to interview the authors may contact Andrew M. McIntosh at +44 (131) 537 6274 or email@example.com.
The authors' affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 5th out of 129 Psychiatry titles and 16th out of 243 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2011 Impact Factor score for Biological Psychiatry is 8.283.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.